CN104997748A - 一种治疗高血压急症的硝苯地平缓释片剂及其制备工艺 - Google Patents
一种治疗高血压急症的硝苯地平缓释片剂及其制备工艺 Download PDFInfo
- Publication number
- CN104997748A CN104997748A CN201510465127.5A CN201510465127A CN104997748A CN 104997748 A CN104997748 A CN 104997748A CN 201510465127 A CN201510465127 A CN 201510465127A CN 104997748 A CN104997748 A CN 104997748A
- Authority
- CN
- China
- Prior art keywords
- release
- nifedipine
- slow
- coating
- pill
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 title claims abstract description 87
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 238000005516 engineering process Methods 0.000 title abstract description 13
- 206010058179 Hypertensive emergency Diseases 0.000 title abstract description 10
- 201000005857 malignant hypertension Diseases 0.000 title abstract description 10
- 229960001597 nifedipine Drugs 0.000 claims abstract description 55
- 238000000576 coating method Methods 0.000 claims abstract description 40
- 239000011248 coating agent Substances 0.000 claims abstract description 35
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 30
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 30
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract description 9
- 239000006187 pill Substances 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 27
- 239000007788 liquid Substances 0.000 claims description 26
- 229950005770 hyprolose Drugs 0.000 claims description 21
- 239000001856 Ethyl cellulose Substances 0.000 claims description 19
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 19
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 19
- 229920001249 ethyl cellulose Polymers 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 16
- 239000012530 fluid Substances 0.000 claims description 15
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 14
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 14
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 14
- 238000005507 spraying Methods 0.000 claims description 14
- 239000006185 dispersion Substances 0.000 claims description 11
- 230000002496 gastric effect Effects 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 238000013268 sustained release Methods 0.000 claims description 10
- 239000012730 sustained-release form Substances 0.000 claims description 10
- 230000004584 weight gain Effects 0.000 claims description 10
- 235000019786 weight gain Nutrition 0.000 claims description 10
- 238000002955 isolation Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 239000007888 film coating Substances 0.000 claims description 7
- 238000009501 film coating Methods 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229960004667 ethyl cellulose Drugs 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 238000013265 extended release Methods 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 4
- 235000013539 calcium stearate Nutrition 0.000 claims description 4
- 239000008116 calcium stearate Substances 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 238000004132 cross linking Methods 0.000 claims description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 3
- -1 wherein Substances 0.000 claims description 3
- 239000005434 MCC/mannitol excipient Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 45
- 239000010410 layer Substances 0.000 abstract description 10
- 239000000463 material Substances 0.000 abstract description 4
- 239000011247 coating layer Substances 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- 239000008188 pellet Substances 0.000 abstract 6
- 229920001531 copovidone Polymers 0.000 abstract 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 27
- 229940079593 drug Drugs 0.000 description 25
- 238000003756 stirring Methods 0.000 description 12
- 239000007962 solid dispersion Substances 0.000 description 7
- 230000001476 alcoholic effect Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 235000010603 pastilles Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 201000001068 Prinzmetal angina Diseases 0.000 description 2
- 208000009325 Variant Angina Pectoris Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000013563 matrix tablet Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000003361 porogen Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510465127.5A CN104997748B (zh) | 2015-08-03 | 2015-08-03 | 一种治疗高血压急症的硝苯地平缓释片剂及其制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510465127.5A CN104997748B (zh) | 2015-08-03 | 2015-08-03 | 一种治疗高血压急症的硝苯地平缓释片剂及其制备工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104997748A true CN104997748A (zh) | 2015-10-28 |
CN104997748B CN104997748B (zh) | 2017-10-13 |
Family
ID=54370796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510465127.5A Active CN104997748B (zh) | 2015-08-03 | 2015-08-03 | 一种治疗高血压急症的硝苯地平缓释片剂及其制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104997748B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105920000A (zh) * | 2016-06-27 | 2016-09-07 | 国药集团广东环球制药有限公司 | 硝苯地平缓释制剂及其制备方法 |
CN108403653A (zh) * | 2018-03-16 | 2018-08-17 | 中国药科大学 | 一种硝苯地平控释包芯片及其制备方法 |
CN108785267A (zh) * | 2018-08-14 | 2018-11-13 | 北京百奥药业有限责任公司 | 一种缬沙坦氨氯地平片及其制备方法 |
CN109568283A (zh) * | 2018-12-28 | 2019-04-05 | 地奥集团成都药业股份有限公司 | 一种硝苯地平缓释片及其制备方法 |
CN117084992A (zh) * | 2023-10-19 | 2023-11-21 | 华润双鹤利民药业(济南)有限公司 | 一种硝苯地平控释片制剂及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090104273A1 (en) * | 1999-06-22 | 2009-04-23 | Elan Pharma International Ltd. | Novel nifedipine compositions |
CN101807716A (zh) * | 2010-03-22 | 2010-08-18 | 庄安中 | 氧化锂动力电池 |
CN103845229A (zh) * | 2012-12-05 | 2014-06-11 | 新昌县冠阳技术开发有限公司 | 一种儿茶素的洗涤剂 |
-
2015
- 2015-08-03 CN CN201510465127.5A patent/CN104997748B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090104273A1 (en) * | 1999-06-22 | 2009-04-23 | Elan Pharma International Ltd. | Novel nifedipine compositions |
CN101807716A (zh) * | 2010-03-22 | 2010-08-18 | 庄安中 | 氧化锂动力电池 |
CN103845229A (zh) * | 2012-12-05 | 2014-06-11 | 新昌县冠阳技术开发有限公司 | 一种儿茶素的洗涤剂 |
Non-Patent Citations (3)
Title |
---|
余裕炳等: "硝苯地平骨架型和膜控型缓释微丸的制备及比较", 《药学与临床研究》 * |
王智军等: "尼莫地平速释微丸及缓释微丸的制备", 《沈阳药科大学学报》 * |
王立等: "流化床包衣法制备硝苯地平缓释微丸", 《中国药学杂志》 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105920000A (zh) * | 2016-06-27 | 2016-09-07 | 国药集团广东环球制药有限公司 | 硝苯地平缓释制剂及其制备方法 |
CN105920000B (zh) * | 2016-06-27 | 2018-10-09 | 国药集团广东环球制药有限公司 | 硝苯地平缓释制剂及其制备方法 |
CN108403653A (zh) * | 2018-03-16 | 2018-08-17 | 中国药科大学 | 一种硝苯地平控释包芯片及其制备方法 |
CN108785267A (zh) * | 2018-08-14 | 2018-11-13 | 北京百奥药业有限责任公司 | 一种缬沙坦氨氯地平片及其制备方法 |
CN109568283A (zh) * | 2018-12-28 | 2019-04-05 | 地奥集团成都药业股份有限公司 | 一种硝苯地平缓释片及其制备方法 |
CN109568283B (zh) * | 2018-12-28 | 2020-08-28 | 地奥集团成都药业股份有限公司 | 一种硝苯地平缓释片及其制备方法 |
CN117084992A (zh) * | 2023-10-19 | 2023-11-21 | 华润双鹤利民药业(济南)有限公司 | 一种硝苯地平控释片制剂及其制备方法 |
CN117084992B (zh) * | 2023-10-19 | 2023-12-26 | 华润双鹤利民药业(济南)有限公司 | 一种硝苯地平控释片制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104997748B (zh) | 2017-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019268052B2 (en) | Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose | |
EP1557179B1 (en) | Analgesic dosage forms that are unable to be inhaled or injected | |
CN104997748A (zh) | 一种治疗高血压急症的硝苯地平缓释片剂及其制备工艺 | |
CS244909B2 (en) | Production method of retarded form of bromohexine | |
KR20010012402A (ko) | 안정한 약제학적 경구 투여형 | |
EP3981399A1 (en) | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor | |
WO2000009133A1 (en) | Sustained release oral preparations of fasudil hydrochloride | |
HU227490B1 (en) | Sustained release pharmaceutical preparation containing carvedilol | |
WO2005084636A2 (en) | A process for the preparation of controlled-release pharmaceutical composition of metoprolol | |
CN109875972B (zh) | 一种奥美沙坦酯氨氯地平药物组合物 | |
CN104814923B (zh) | 一种盐酸坦洛新缓释制剂及其制备方法和其应用 | |
CA2823622C (en) | Solid molecular dispersion of fesoterodine | |
KR20140021985A (ko) | Mups (다중단위 펠릿 시스템) 태블릿 형태의 경구형 에소메프라졸 약학 제형 | |
EP2533766A2 (en) | Pharmaceutical mini-tablets for sustained release of flecainide acetate | |
EP1216032B1 (en) | Oral controlled release formulations | |
CN102247366B (zh) | 包括依那普利和非洛地平的药物组合物缓释制剂 | |
CN105431140B (zh) | 含有缓释二甲双胍和速释HMG-CoA还原酶抑制剂的复合制剂 | |
CN103301083B (zh) | 一种硝苯地平缓释片剂及其制备方法 | |
CN102793658A (zh) | 一种含有麦考酚酸或麦考酚酸盐的骨架型制剂及其包衣片 | |
CN104758266B (zh) | 一种非洛地平缓释片及其制备工艺 | |
CN105816436B (zh) | 一种泮托拉唑肠溶微丸、泮托拉唑肠溶缓控释片剂及其制备方法 | |
RU2411035C2 (ru) | Лекарственная форма с модифицированным высвобождением 6-метил-2-этил-3-гидроксипиридина сукцината | |
KR101990951B1 (ko) | 리바스티그민 함유 서방출 의약조성물 | |
CN1529587A (zh) | 含有粪便软化剂泊洛沙姆和包有肠溶衣的比沙可定颗粒的药物组合物 | |
CN113262206A (zh) | 硝苯地平制剂的制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Fan Xinhua Inventor after: Zhou Yueyu Inventor after: Zhang Xiang Inventor after: Zhu Ji Inventor after: Zhang Mingjie Inventor after: He Bin Inventor before: Bai Qiang |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170907 Address after: 213004 No. 567 Wu Cheng Road, Changzhou, Jiangsu Applicant after: Changzhou City No.4 Pharmaceutical Factory Co., Ltd. Address before: 721013 Baoji Province, Weibin District, high tech Avenue, No. 85, Tianqi Pharmaceutical Co., Ltd., Applicant before: Bai Qiang |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20151028 Assignee: Pharmaceutical Co., Ltd., Changzhou Pharmaceutical Factory No.4 Assignor: Changzhou City No.4 Pharmaceutical Factory Co., Ltd. Contract record no.: 2018320000315 Denomination of invention: Nifedipine slow-release tablet for treating hypertensive emergency and preparation technology thereof Granted publication date: 20171013 License type: Exclusive License Record date: 20181114 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191217 Address after: 213018 middle Wu Avenue, Tianning District, Changzhou, Jiangsu Province, No. 567 Co-patentee after: Pharmaceutical Co., Ltd., Changzhou Pharmaceutical Factory No.4 Patentee after: Changzhou City No.4 Pharmaceutical Factory Co., Ltd. Address before: 213004 No. 567 Wu Cheng Road, Changzhou, Jiangsu Patentee before: Changzhou City No.4 Pharmaceutical Factory Co., Ltd. |